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Objectives. To study the short-term effect of eye opening and use of topical dexamethasone phosphate 0.1% and levofloxacin 0.5%
on the cytokine levels in human tears. Methods. Prospective experimental design was used for tear collection from eyes of 10
healthy controls and 20 patients four days after penetrating keratoplasty (PKP) at awakening and after instilling dexamethasone or
levofloxacin.The concentrations of different cytokines were measured by cytometric bead array. Results. At eye opening, IL-6 levels
were higher in the PKP group as compared to the controls. Thirty minutes later, the released levels of IL-10, IL-13, IL-17, IFN𝛾, and
CCL5 increased in controls, while CXCL8 decreased in both control and PKP groups. The release of the cytokines remained stable
after 30mins except for IFN𝛾, which showed a decrease in the controls following levofloxacin instillation. No short-term effects of
the topically used dexamethasone and levofloxacin could be detected on the cytokine levels in controls and after PKP. Conclusions.
Evidence of changes in the levels and time course of tear cytokines after awakening or eye opening could be established and the
short-term confounding effects of dexamethasone and levofloxacin on the levels of released cytokines in human tears could be
excluded.
1. Introduction
The preocular tear film is essential for maintaining ocular
surface homeostasis and the tear samples may be a use-
ful source of information for understanding the molecular
mechanisms behind several eye diseases. With improvement
of analytical methods and high-throughput technologies,
studies quantifying the levels of mediators in human tears
have gained increased value [1–4], while studies performed
during the postoperative period are desired.
Beside accurate sampling of tears, many confounding
factors can modify or affect the results obtained from tear-
release studies: timing of tears’ collection (open- or closed-
eye phase), instillation of eye drops, age, sex, tear flow
rate, collection technique, different methods for measuring
cytokines, pooling, centrifugation, and storage of the samples
[1–15].
The tear film has been extensively studied in the open-
eye state, and some studies have shown that eye closure
results in a profound change in tear composition [1, 14, 16,
17]. During sleep, subclinical inflammatory state takes place,
which has a great importance in the pathomechanism of
several eye diseases [1, 16]. The closed-eye state induces the
recruitment and activation of polymorphonuclear (PMN)
cells [17], and because of reduced tear film clearance, the
cytokine levels may be modified as well. The levels of IL-
1, IL-6, IL-8, IL-10, IL-12p70, and TNF-𝛼 have been inves-
tigated previously following three-hour eye closure, without
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providing information about the time needed for tear film
recovery from the closed-eye state [3, 18]. Information about
recovery time is important for valid comparative studies of
tear cytokines. Closed-eye tear samples, which have been
recovered immediately after overnight eye closure, have been
first described by Sack et al. [16]. Changes in the levels of
cytokines, proinflammatory mediators, and growth factors
during overnight eye closure, however, have been of limited
research interest so far [17].
The timing of tear sample collection is not a standardized
procedure, although the time after awakening and after
application of local treatment can influence the levels of
several mediators, thereby modifying the overall clinical sit-
uation. Topical application of fluoroquinolones and steroids
has become a common treatment after ophthalmic surgeries
including corneal transplantation (keratoplasty) [19, 20], but
very little is known about their short-term effects on the
cytokine levels of the tear film.
To study the short-term effects of awakening and the use
of topical dexamethasone and levofloxacin on cytokine levels
in human tears, we measured the concentration of multiple
cytokines in tear samples of controls and patients treated
by penetrating keratoplasty (PKP). Additional evidence on
the alteration of a wide range of tear cytokines collected
after awakening or eye opening could be demonstrated,
while short-term confounding effects of dexamethasone and
levofloxacin on the cytokines in human tears could be
excluded.
2. Patients and Methods
2.1. Subjects, Tear Collection, and Analysis. All human tear
samples were obtained with a written patient consent accord-
ing to the tenets of the Declaration of Helsinki and sample
collection procedures were approved by the Regional Ethics
Committee of the University of Debrecen.
Within a prospective study, nonstimulated tear samples
were collected from 20 eyes of 20 patients (mean age: 66.7
years, SD: 16.9) four days after PKP and from 10 eyes of 10
healthy controls (mean age: 68.6 years, SD: 16.9). All donor
corneas were preserved in Optisol-GS (Bausch & Lomb,
USA) for at most 7 days. Routine medications, local corticos-
teroids (dexamethasone phosphate 0.1% (Maxidex, Alcon))
and antibiotics (levofloxacin 0.5% (Oftaquix, Santen Oy)),
were applied at four time points (four eye drops of each drug
per day) after corneal transplantation. None of the patients
received systemic anti-inflammatory therapy (intravenous or
oral corticosteroids). Exclusion criteria for controls included
active inflammatory or infective systemic or ocular diseases,
current treatment with systemic or local anti-inflammatory
drugs, and patients with contact lenses. Eyes with previous
ocular surgery or trauma were also excluded from the study.
The causes for corneal transplantation were keratoconus,
bullous keratopathy, transplant rejection, corneal vascular
leucoma, and corneal scar.
Before every tear collection, the anterior ocular status of
each subject was carefully assessed; a slit-lamp examination
under low illuminationwas performed to avoid reflex tearing.
Sample collection was always performed by the same person.
All the study participants were asked not to open their
eyes before sample collection. At day 4 after surgery, the
reepithelisation of the transplanted cornea in our study
reached in all cases a continuous epithelial layer. Tears were
collected from each eye at 6:00 (upon eye opening after
overnight sleep), 6:30, 6:40 (10mins after instilling an eye
drop of dexamethasone), 6:50, and 7:00 a.m. The eyes were
treated with one eye drop of dexamethasone phosphate at
6:30 a.m., followed by one drop of levofloxacin at 6:50 a.m.All
drops were instilled into the inferior cul-de-sac. Drops were
administrated by a doctor to ensure strict compliance with
the administration regimen.
Nontraumatic tear collection was carried out with capil-
lary tubes from the inferior meniscus without topical anes-
thesia for 2mins and then the total volume of each collected
tear sample was registered. The samples were immediately
transferred to Eppendorf tubes and frozen at –80∘C without
centrifugation within 15min from collection. To avoid pipet-
ting and dilution errors, collected tear samples of <4 𝜇L were
excluded. Occasionally, tear collection could not be carried
out due to dry eyes.
The concentrations of IL-1𝛽, IL-6, IL-10, IL-13, IL-17,
IFN𝛾, IL-8/CXCL8, IP-10/CXCL10, and RANTES/CCL5were
measured by the cytometric bead array (CBA) method.
Combined FlowCytomix Simplex Kits were used with the
appropriate FlowCytomix Basic Kit withminormodifications
from the manufacturer’s instructions (eBioscience, Bender
MedSystems GmbH, Vienna, Austria). Briefly, 15 𝜇L of tear
samples (in some cases, in Assay Buffer 2–10x diluted
samples) or serial dilutions of mixed standard cytokines
were added to 15 𝜇L suspension of fluorescent cytokine
capture beads on multiwell filter microplates. 15 𝜇L of biotin
conjugated anti-cytokine antibody was added to the wells,
and the plateswere then incubated for 2 hours on amicroplate
shaker. The wells were emptied and washed with a vacuum
filtration manifold. Phycoerythrin-conjugated streptavidin
was added to the wells followed by additional incubation
for 1 hour and washing as described above. 150 𝜇L assay
buffer was applied to the wells; then multiparametric data
acquisition was performed on a FACS Array cytometer
(BD Biosciences Immunocytometry Systems, San Jose, CA).
Data were analyzed with the FlowCytomix Pro 2.3 software.
Additional serial dilutions of the standard were applied to
obtain better sensitivity and, therefore, modified standard
curves were generated in the analysis. In cases of diluted
samples, the end concentration of the sampleswere calculated
accordingly. The detection limits were IL-1𝛽: 4.2 pg/mL;
IL-6: 1.2 pg/mL; IL-10: 1.9 pg/mL; IL-13: 4.5 pg/mL; IL-17:
2.5 pg/mL; IFN𝛾: 1.6 pg/mL; IL-8/CXCL8: 0.5 pg/mL; IP-
10/CXCL10: 6.0 pg/mL; RANTES/CCL5: 25 pg/mL.
2.2. Statistical Methods. The quantities of mediators released
into tears were calculated as products of concentrations
(pg/𝜇L) and tear volumes (𝜇L) collected over 2mins. Con-
tinuous variables were described in each patient group and
in the overall study sample using standard statistics.
Analysis of correlation between clinical data and CBA
data was performed using unadjusted as well as adjusted
estimation procedures. Cytometry data were geometrically
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Table 1: Clinical data and total volume of tears collected by each subject in PKP patients and controls.
PKP patients Controls Statistics
Gender (female :male) 12 : 8 7 : 3 Fisher’s exact test: 𝑃 = 0.70
Age (mean; (SD)) 68.7 (16.9) 66.7 (16.9) Wilcoxon rank-sum test: 𝑃 = 0.83
Collected total tear volume by each subjects (𝜇L, mean; (SD)) 50.2 (22.9) 42.1 (39.7) Wilcoxon rank-sum test: 𝑃 = 0.07
averaged across measurement occasions to derive a single
value for each patient. Spearman’s correlation coefficients
were used to estimate unadjusted correlations. Adjusted
estimates were semipartial correlation coefficients derived
from multiple linear regression models with patient group,
age, sex, and total volumeof collected tear fluid as explanatory
variables and each cytometry variable in turn as the outcome
variable.
Unadjusted intergroup differences at baseline (6:00 a.m.)
and at 6:30 a.m. were tested using the t-test or a nonpara-
metric equivalent subject to distributional assumptions being
satisfied. Age-adjusted comparisons were carried out using
multiple linear regression.
Within-group differences of release levels across mea-
surement occasions and between-group differences of release
levels adjusted for the previous measurement were assessed
using multiple linear regression with adjustment for age
and with an interaction term between patient group and
measurement occasion. The models were checked by testing
for heteroskedasticity and regression specification errors.
Variables were transformed to improve normality unless
this failed to produce substantially better fit assessed by
normality of standardized residuals.
The statistical package applied was Stata version 11.2. The
significance criterion was set at 𝛼 = 0.05. All 𝑃 values shown
are from adjusted analyses unless stated otherwise. Power
analysis was performed to justify the number of patients
enrolled in the study.
3. Results
Differences in gender, age, and volume of collected tear fluids
could not be detected between the patient and the control
group (Table 1). The average collected tear fluid volume
was 10.1 𝜇L (SD: 5.9) in PKP group and 8.8𝜇L (SD: 9.4) in
control group. The variable amounts of collected tear fluid
were calculated and the release levels of the mediators were
measured.
The correlation analyses between clinical data and cytom-
etry bead array data using unadjusted as well as adjusted
estimation procedures are shown in Table 2. Age with CXCL8
and total tear volume with IL-13 correlated significantly,
irrespective of the estimation procedures. Age with IFN𝛾
and IL-10 and total tear volume with CXCL8 correlated
significantly if adjusted estimation procedures were used
and total tear volume with IP-10 correlated significantly if
unadjusted estimation procedure was used.
At baseline (6:00 a.m., awakening or eye opening), higher
IL-6 level was detected after PKP as compared to controls
(𝑃 < 0.0001 unadjusted, 𝑃 = 0.0153 adjusted for age). Thirty
minutes after eye opening the release of IL-10 (𝑃 = 0.004),
IL-13 (𝑃 = 0.0005), IL-17 (𝑃 = 0.007), IFN𝛾 (𝑃 = 0.003),
and CCL5 (𝑃 = 0.0009) increased in the controls, while
the release of CXCL8 decreased (𝑃 = 0.0007). Under the
same conditions, the release of CXCL8 decreased in the PKP
group as well (𝑃 = 0.02) (Figure 1 and Table 3). The cytokine
release remained stable after 30mins after eye opening and
throughout the time interval of examination except for IFN𝛾
which decreased after using levofloxacin eye drop in the
control group (𝑃 = 0.02) (Figure 2).
4. Discussion
The question of the effects of eye closure on tear film
compositionwas first raised 35 years ago [21], and subsequent
investigations on the effects of overnight eye closure as a con-
tributing factor have been reported to explain the discrepan-
cies in data reported in the literature [1, 14, 16, 17]. Indeed, tear
collection time, flow rate, stimulus conditions, and collection
techniques [14, 22]may contribute to the variation of cytokine
concentrations measured in tear samples and may influence
the protein profile of the tear samples [5–7, 9]. Besides the
precise and reproducible determination of tear protein levels,
the uniform interpretation (concentration versus release), the
time after opening the eye, and the local treatment applied
have crucial impact on the levels of different mediators.
Without understanding how various soluble factors influence
the released and measured cytokine levels, the integration
and reliability of the data obtained from different studies
remain problematic. In this study changes in cytokine levels
measured in tear fluids of healthy controls and PKP patients
in response to awakening or eye opening and treatment
with topical dexamethasone phosphate and levofloxacin were
studied. The effects of awakening on the release of nine
cytokines in human tear samples were investigated.We found
that the levels of IL-10, IL-13, IL-17, IFN𝛾, and CCL5 were
lower in the closed-eye tears, while the level of CXCL8 was
higher at eye openingwhen compared to the valuesmeasured
30mins later.These findings are in linewith numerous studies
showing alterations in tear fluid composition after awakening
[1, 3, 10, 14, 16, 17]. During sleep or eye closure, physiological
changes occur in the ocular surface causing a local subclinical
inflammatory state [1, 16]. Studies have shown that eye closure
results in a profound change in the composition, origins,
turnover, and physiological functions of the tear film with
the accumulation of various cytokines and mediators [17].
A specific diurnal alteration pattern of IL-1𝛽, IL-6, CXCL8,
IL-10, IL-12p70, and TNF𝛼 has been found showing the
importance of the timing of tear collection during the day [2].
It is noteworthy that the examination of different cytokines
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Figure 1: Concentration ofmediators in released tear samples at baseline (0min, awakening or eye opening) and 30minutes after eye opening
in PKP patients and controls. Values shown were obtained by applying scaling factors where indicated (∗).
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Figure 2: Concentration of released mediators 40-50-60 minutes after eye opening in PKP patients and controls. Treatment with one eye
drop of dexamethasone phosphate at 30 minutes and one drop of levofloxacin at 50 minutes after awakening or eye opening was carried out.
Values shown were obtained by applying scaling factors where indicated (∗).
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Table 3: Medians (interquartile ranges) of released cytokine quantities (pg) at awakening (0min) and 30 minutes after eye opening (∗ had
𝑃 ≤ 0.007) in PKP patients and controls.
IL-10 IL-13 IL-17
0min 30min 0min 30min 0min 30min
Controls 1.3 (1.5) 5.2∗ (4.6) 1.5 (1.0) 4.2∗ (2.3) 0.1 (0.4) 1.7∗ (2.2)
PKP patients 3.0 (3.7) 1.5 (3.0) 2.9 (2.2) 2.3 (1.7) 0.8 (1.1) 0.3 (1.1)
IFN𝛾 CXCL8 CCL5
0min 30min 0min 30min 0min 30min
Controls 0.8 (0.8) 3.9∗ (3.7) 86.8 (52.5) 36.3∗ (52.6) 2.0 (1.1) 7.1∗ (6.0)
PKP patients 2.3 (2.2) 1.2 (2.1) 54.1 (54.6) 32.8∗ (34.8) 4.5 (5.3) 2.6 (4.2)
present in overnight tears has been reportedmainly in control
[1, 10] and allergic eyes [14].
In the present study, only the IL-6 level was higher in the
tear samples of patients after PKP at awakening compared to
the controls; this was in accordance with our earlier reports
[23]. IL-6 is a highly sensitive indicator of various types of
irritative eye diseases and high levels of it have been detected
in closed-eye tears [10]. In contrast to these results, we
demonstrated that awakening caused no significant alteration
in IL-6 levels in both the controls and the patients. Previously,
Thakur et al. could not detect IL-6 in normal open-eye tear
samples that could have been due to inappropriate sensitivity
of the IL-6 assay used for detection [10]. The level of the
anti-inflammatory cytokine IL-10 increased after awakening,
which is consistent with previous reports showing the induc-
tion of a subclinical inflammatory state during 3-hour eye
closure [3].
Among the TH2-related cytokines, IL-13 is known as a
normal constituent of human tears [15], although it has also
been detected in pathological tear samples [24]. In our study,
the release level of IL-13 increased after eye opening in the
controls, but no alteration was observed after awakening in
the patient group. Low levels of IL-13 have been detected
in severe keratoconus [25], as well as high levels in Graves’
orbitopathy [26].The exact function of IL-13 upon eye closure
requires further investigation.
Interestingly, 30mins after eye opening the release level
of CXCL8 decreased in our patient group, while the concen-
tration of the other cytokines remained unchanged, pointing
to the fact that a four-day use of topical dexamethasone
and levofloxacin can profoundly modulate the level of the
measured cytokines. Furthermore, these treatments can also
reduce cytokine levels due to awakening. A higher level of
CXCL8 was found in the closed-eye tears of the controls,
consistent with some previous reports showing that CXCL8,
acting predominantly as a chemoattractant, was increased in
the tear fluid during sleep [10, 12, 17].
Previously, Jun et al. [27] have shown that lower levels
of CCL5 were found in keratoconic patients but contact lens
wear had no significant effect on it in our study and a sig-
nificantly increased CCL5 level was detected after awakening
in the controls showing that this chemokine may have less
function during sleep.
Recently, the roles of IL-17 and IFN𝛾 have been inves-
tigated in ocular diseases; however, to the best of our
knowledge, the effect of awakening on these cytokines has
not yet been investigated. The tear levels of IL-17 and IFN𝛾
were higher 30mins after awakeningwhen compared to those
immediately after eye opening.
The short-term effect of topical treatment on the level
of cytokines released in tears has previously been studied
without involving sample collection at 24 hours [14]. Another
study in which exclusion criteria for patients treated by anti-
inflammatory agents has also been published [12]; however,
there are many patients who cannot be left without med-
ication for such a long period of time. To the best of our
knowledge, this is the first report demonstrating the lack of
short-term effects of topical dexamethasone and levofloxacin
on the cytokine levels in human tears even after PKP, since
these treatments did not influence the release of the examined
cytokines within 30 minutes from administration (except
IFN𝛾).
Steroids have been widely used in ophthalmology [28]
and they exert a strong anti-inflammatory effect on inflam-
matory cytokine production.The mainstream in the prophy-
laxis of immune reactions after PKP is still the administration
of topical corticosteroids during the postoperative period,
but the short-term effects of steroids on cytokine levels in
the human tear film have not been studied so far. Our
results demonstrate that one drop of dexamethasone had no
short-term effect on the cytokine levels in tears, although
long-term effects were not monitored after PKP, when the
patients received topical steroids continuously. Regulation
of cytokine levels in the human tears and the duration of
their downregulation await further analysis. Topically applied
dexamethasone did not cause significant changes in colony
counts on a healthy conjunctiva [20] and the expression
of several proinflammatory genes has been shown to be
attenuated by dexamethasone [29], and this treatment in vitro
has been found to inhibitmatrix protein deposition andfibro-
sis, thereby maintaining corneal clarity [29]. Steroids retard
corneal epithelial healing [30] and systemic administration
of betamethasone was able to suppress the inflammatory
cytokine expression (IL-1, IL-6, and IL-8) in a rat cornea
model [31].
Fluoroquinolones are antibacterial agents with bacteri-
cidal activity. Levofloxacin, like other quinolones, has an
immunomodulatory action on the cytokine production at an
early transcriptional step of cytokine gene expression [32,
33]. Suppression of IL-6 by quinolones has been proven in
vitro [34]. Fluoroquinolones penetrate efficiently into eyes
with disrupted epithelium [35]. After a short-term usage of
Journal of Immunology Research 7
levofloxacin eye drops, high corneal and aqueous humor
concentrations of this quinolone can be reached [19, 36, 37].
Four days after PKP the epithelium is not yet perfectly intact,
so high aqueous humor concentration of levofloxacin is
presumed; however, no information is available on the short-
term effects of the use of topical levofloxacin on the cytokine
levels in human tears. Our study followed the changes in the
cytokine levels after 10mins from instillation of levofloxacin
eye drops. As 15mins is usually needed for the penetration of
levofloxacin to the cornea, it may persist in the tear film caus-
ing an alteration in the level of cytokines [19, 36, 37]. When a
drop of one medication is followed closely by drops of other
medications, substantial washout and pH change may occur
[36]. We set a 10 min interval between the administrations of
each eye drop to minimize the above effects. Administration
of levofloxacin has been found tomodify the levels of IL-1, IL-
6, IL-8, andTNF-𝛼 in a time- and/or dose-dependentmanner
[38, 39]. In our study, after administration of a levofloxacin
eye drop the release of the cytokines remained stable for 10
minutes except for IFN𝛾, which decreased in the controls.
We could not detect any short-term effects of topically used
levofloxacin on the cytokine levels in tears after PKP. A
possible explanation for this effect could be that levofloxacin
is one of the fluoroquinolones, which causes less influence
on the concentration of released cytokines as compared to
other drugs. In addition, the 10mins time may have been
enough for the eye drop to wash out, but not enough to cause
a significant effect.
The large plethora of mediators found in the tears makes
it impossible to conclude from the present study that lev-
ofloxacin and dexamethasone have no short-term effects on
the levels of all mediators found in tears. This study was
restricted to a total of 9 measured cytokines, which can be
further expanded with the availability of high-throughput
multiplex bead array technology. Nevertheless, it is important
to emphasize that our results highlight the fact that the levels
of many cytokines and mediators in the tear fluid change
after awakening, and levofloxacin and dexamethasone have
little short-term effect on these mediators. Our findings raise
several questions as to whether there are other cytokines and
chemokines that could be affected after short-term use of
steroids or antibiotics, and the degree in which other topical
treatments may affect the level of the tear mediators. Since
steroid eye drops are often administered in ocular surface
disorders, it is necessary to investigate the long-term effects
of prolonged use of corticosteroids on tear mediators.
To the best of our knowledge, this study presents for
the first time the fact that not only normal, but also
pathological, conditions may exert limited and/or short-
term effects after the use of levofloxacin and dexamethasone
on the levels of tear cytokines. Our data demonstrate that
the release of IL-1𝛽, IL-6, and CXCL10 is not altered after
successive administration of levofloxacin and dexamethasone
in both the control and the pathological tear samples. Since
cytokines and other mediators have been implicated in the
pathophysiology of a wide range of corneal diseases, gaining
knowledge about the different confounding factors affecting
the cytokine levels in tears was shown to be appropriate.
We further demonstrated the importance of timing and the
urgent need of commonly accepted guidelines or collection
techniques for tear collection. Collection of tear samples
between 9 and 12 a.m. [24] and the arguments suggesting
morning collection before the first eye drops are instilled
[40] need better coordination and/or revision. In summary,
additional evidence for the concentration changes in a wide
range of tear cytokines after awakening or eye opening could
be established and the short-term confounding effects of
dexamethasone and levofloxacin on the cytokines present in
human tears could be excluded.
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